HomepageProducts & ServicesProduct & Service News > Stago Offers the Only Commercially Available Monoclonal Antibodies Anti-Human GPVI

Stago Offers the Only Commercially Available Monoclonal Antibodies Anti-Human GPVI

Back to list

2014/09/25: Glycoprotein VI (GPVI), a major collagen receptor playing a crucial role in collagen-induced platelet activation and aggregation, is a ~62-kDA type 1 transmembrane receptor belonging to the immunoglobulin superfamily.

As well as collagen, other ligands such as collagen-related peptide (CRP) and snake venom protein (convulxin), can bind to the extracellular region of the GPVI causing ectodomain GPVI shedding. This metalloproteinase-regulated process provides a mechanism for the modulation of platelet responsiveness.  

While most GPVI is maintained in a monomeric form on resting platelets, GPVI dimerization is an active process that primes platelet interaction with fibrillar collagen.

In order to be utilized in research studies investigating platelet function and surface expression of GPVI, Stago provides a monoclonal antibody (mAb) against Human GPVI in a purified and –PE conjugated form. Stago’s purified anti-Human GPVI (Cat. # 01083) is available in 0.1mg/mL in 1 mL packaging. The anti-Human GPVI PE conjugated item (Cat. # 01084) is available in 100 test kits in 2 mL packaging. These antibodies are designed for use in a quantitative fashion along with the PLATELET Calibrator kit (Cat # 00457).

These anti-Human GPVI antibodies and associated kits are for research use only in the U.S. and Canada (not for use in diagnostic procedures).


Nichole Howard, Marketing Communications Specialist
Diagnostica Stago, Inc.